Lupin Limited has informed the Exchange regarding Change in Director(s) of the company.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited's Board has approved the re-appointment of Mr. Mark D. McDade as an Independent Director for a second term of five consecutive years, effective from January 28, 2026 to January 27, 2031. The decision was made on the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval. Mr. McDade has over 40 years of experience in the biopharmaceutical industry, with expertise in corporate governance, leadership, healthcare, manufacturing, ESG, and M&A. He holds a Bachelor's degree from Dartmouth College and an MBA from Harvard Business School. He is not related to any existing Directors, KMPs, or Promoters of the company and is not debarred from holding directorship by any regulatory authority.
This is a routine governance announcement with no material impact on the stock price. It signals board continuity, as the company retains an experienced independent director with strong pharma industry credentials for another five-year term.